A neuromuscular perspective of sarcopenia pathogenesis: deciphering the signaling pathways involved

Geroscience. 2022 Jun;44(3):1199-1213. doi: 10.1007/s11357-021-00510-2. Epub 2022 Jan 4.

Abstract

The escalation of life expectancy is accompanied by an increase in the prevalence of age-related conditions, such as sarcopenia. Sarcopenia, a muscle condition defined by low muscle strength, muscle quality or quantity, and physical performance, has a high prevalence among the elderly and is associated to increased mortality. The neuromuscular system has been emerging as a key contributor to sarcopenia pathogenesis. Indeed, the age-related degeneration of the neuromuscular junction (NMJ) function and structure may contribute to the loss of muscle strength and ultimately to the loss of muscle mass that characterize sarcopenia. The present mini-review discusses important signaling pathways involved in the function and maintenance of the NMJ, giving emphasis to the ones that might contribute to sarcopenia pathogenesis. Some conceivable biomarkers, such as C-terminal agrin fragment (CAF) and brain-derived neurotrophic factor (BDNF), and therapeutic targets, namely acetylcholine and calcitonin gene-related peptide (CGRP), can be retrieved, making way to future studies to validate their clinical use.

Keywords: BDNF; CAF; Denervation; Muscle wasting; Neuromuscular junction; Neurotrophins.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aging / physiology
  • Humans
  • Muscle Strength
  • Neuromuscular Junction / metabolism
  • Sarcopenia*
  • Signal Transduction